Bactericidal Bacteriostatic Activity
Bactericidal Bacteriostatic Activity - Related Videos
05:40
A Serum Bactericidal Assay for the Complement-Mediated Bactericidal Activity of Antibodies
0 Views •
2025
This video demonstrates a technique to evaluate the complement-mediated bactericidal activity of antibodies present in serum. This approach combines isolated serum with pathogenic bacteria and exogenous complement proteins. Upon incubation, the bacteria are grown on an agar plate, and the produced colonies are quantified to measure the serum bactericidal titer.
02:55
Determining the Role of Vitronectin in Bacterial Resistance to Bactericidal Activity of Human Serum
0 Views •
2025
This video demonstrates the role of vitronectin, a human serum glycoprotein, on bacterial resistance. Antibodies in the serum interact with bacterial surface proteins, activating complement proteins and forming the membrane attack complex, causing bacterial cell lysis. Vitronectin binding on bacterial membrane protein prevents the membrane attack complex formation, resulting in bacterial survival.
07:28
Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
0 Views •
Cited by 4 •
2020
The elucidation of the mode-of-action of a novel antibiotic is a challenging task in the drug discovery process. The goal of the method described here is the application of isothermal microcalorimetry using calScreener in antibacterial profiling to provide additional insight into drug-microbe interactions.
06:08
A Charcoal Agar Resazurin Assay to Evaluate Test Compound Activity Against Mycobacteria
0 Views •
2025
This video showcases the Charcoal Agar Resazurin Assay (CARA) for evaluating the activity of antimicrobial compounds against Mycobacterium tuberculosis. CARA aids in assessing the efficacy of these compounds by gauging their impact on bacterial growth and distinguishing between bactericidal and bacteriostatic effects.
06:11
A High-throughput Shigella-specific Bactericidal Assay
0 Views •
Cited by 6 •
2019
Here we present a protocol to measure Shigellacidal activity of antibodies in serum. Serum is mixed with bacteria and exogenous complement, incubated, and the reaction mixture is plated on agar plates. Viable bacteria form colonies which are counted, using an automated colony enumerator, and used to determine the bactericidal titer.
FAQs
The observed effect can change with both drug concentration and the length of bacterial exposure. An agent may produce different laboratory results when either variable changes, so activity should not be interpreted independently of testing conditions. Recording these factors helps researchers distinguish a genuine difference in antimicrobial performance from an outcome caused by an altered experimental setting.
The affected bacterial process helps explain whether exposure produces growth suppression or more lasting loss of viability. Membrane disruption, cell wall damage, and irreversible interference with essential cellular processes can support killing, while inhibition of protein or nucleic acid synthesis primarily limits population expansion. Linking the result to its cellular target strengthens mechanistic interpretation.
Yes. The same antimicrobial effect should not be assumed to occur identically across bacterial species, because the overview identifies species as one factor that can influence activity. This variability makes organism-specific susceptibility testing important for interpreting laboratory findings and for selecting an approach to infection treatment rather than relying only on an agent’s general classification.
MIC and MBC provide complementary measurements for examining antimicrobial performance. Together, they help indicate the conditions associated with inhibited bacterial growth and those associated with bactericidal effects. Using both measures gives laboratory interpretation more resolution than relying on a single observation, particularly when concentration, exposure time, or bacterial species may alter the outcome.
Assessment centers on antimicrobial susceptibility testing under defined conditions, followed by interpretation of growth-related and killing-related measurements. Researchers account for the tested bacterial species, drug concentration, and exposure time, then use MIC and MBC results to characterize the response. This workflow supports comparisons among agents and provides evidence for antimicrobial selection.
The distinction connects antimicrobial effects with host-pathogen interactions and antimicrobial resistance research. Treatment studies can examine whether an agent mainly limits bacterial expansion or produces killing, while infection models can relate that outcome to the host environment. Susceptibility results also support investigation of resistance by showing how bacterial responses change under antimicrobial pressure.